All Over For AZ's Fasenra In COPD With Second Trial Fail

 
• By Kevin Grogan

It is curtains for AstraZeneca's asthma therapy Fasenra as a COPD treatment after the failure of the TERRANOVA trial, which could be good news for GSK's fellow interleukin-5 drug Nucala, despite the latter's own mixed Phase III data.

extinguished candle yellow with smoke, isolated over black
Hopes for Fasenra in COPD extinguished • Source: Shutterstock

More from Clinical Trials

More from R&D